MDM2 oncogene as a novel target for human cancer therapy.
about
Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2Isolation, in silico characterization and chromosomal localization of a group of cDNAs from ciliated epithelial cells after in vitro ciliogenesisPhase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathwayFrom laptop to benchtop to bedside: structure-based drug design on protein targets.Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.E3 ubiquitin ligases as cancer targets and biomarkers.Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.p53 gene in treatment of hepatic carcinoma: status quo.Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structuresThe MDM2-p53 pathway revisitedPlatycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivoEvaluation of Chlorofusin, its Seven Chromophore Diastereomers, and Key Analogues.The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interactionPeriod2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway.Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.Role of E3 ubiquitin ligases in lung cancer.MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression.The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation.Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.
P2860
Q24337403-EC4F0DAE-2DD2-4CFD-AB70-9B43C723D529Q24803661-0ECCDBFE-4BCE-4EAA-8A1B-6749BD988F5FQ33439682-1DEC6434-2887-43AC-ABD8-903696A6405BQ33572309-52484462-5DE1-47C8-AA63-ABA73C307E02Q34119145-EEFEA123-A5DD-4782-8C41-9E3A44BF2509Q34153589-D3E9C2D8-ABD7-452A-B1CA-D834A544F4EAQ34218811-6BE38E97-E18B-42BB-A563-1F2D38D6F68CQ34388038-679BE203-69DE-4731-BC9E-440304A911BEQ35082710-C4378A53-2D42-4E3B-9D82-5E666A838980Q35311244-43ADC9BE-6B0B-456E-8EB7-132F6476D9A5Q36161416-557A7988-6023-445B-B965-429B9F180A4CQ36323374-24C4A1D5-325E-4C65-B04C-E767D12BB683Q36764842-E7E58A3E-E13B-4FF6-8030-9278CDB2ADC0Q36983259-0C4C5D6F-B7D5-46EE-80FB-5148DFDDE7D5Q37039474-ED2CAD7E-EF82-4C0F-9B52-A8EF2915A221Q37204077-4DDDF4C9-62D0-418C-8E89-9C8B7D7679DEQ37231202-46C9CA78-373B-463D-86AD-B3CEA2B79DF1Q37286347-84C9CF42-2EF0-4FEE-94D7-019FEE2CF6EBQ37317259-F8CE548E-9103-48C2-8E66-AA45DD20807EQ37422728-E55AEA7B-E326-46D6-A60B-1CDBDCF6B115Q38128316-ED5B7B24-F102-4857-9490-507D5E0C88CBQ38345102-5D01A2E7-FE17-4913-8E5E-E1F76059EA72Q38710594-B57B6543-A7AF-4242-AB65-F251A06A3ABDQ39855621-D2BFD958-6DFF-4E0C-9294-88BECB3BA2D4Q40107851-BF62AF91-4EDD-4AB5-B847-0A34A19FB47BQ40738795-D21BAD8C-5FB8-477D-9CD4-FCCB00709D44Q42427815-D40976B7-3E95-4B2E-8557-F353C00CDEA9Q53620032-BE6ECE49-B2A5-49CC-A179-DAB455A712C7
P2860
MDM2 oncogene as a novel target for human cancer therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
MDM2 oncogene as a novel target for human cancer therapy.
@ast
MDM2 oncogene as a novel target for human cancer therapy.
@en
type
label
MDM2 oncogene as a novel target for human cancer therapy.
@ast
MDM2 oncogene as a novel target for human cancer therapy.
@en
prefLabel
MDM2 oncogene as a novel target for human cancer therapy.
@ast
MDM2 oncogene as a novel target for human cancer therapy.
@en
P356
P1476
MDM2 oncogene as a novel target for human cancer therapy.
@en
P304
P356
10.2174/1381612003400911
P577
2000-03-01T00:00:00Z